Overview of naphthalimide analogs as anticancer agents
- PMID: 19929786
- DOI: 10.2174/092986709789909576
Overview of naphthalimide analogs as anticancer agents
Abstract
Cancer, which accounted for 7.9 million deaths (around 13% of all deaths) in 2007, is a leading cause of death in the world. Deaths from cancer worldwide are projected to continue rising, with an estimated 12 million deaths in 2030. Therefore, the rapid increase in the cancer burden represents a real crisis for public health and health systems worldwide. Although cancer chemotherapy will cause side effects and drug resistance, it is still recognized as the first choice for the treatment of many cancers. To our knowledge, naphthalimide (1H-benzo[de]isoquinoline-1,3-(2H)-dione) analogs have been considered as one promising and potential class of anticancer agents against human tumor cells, such as amonafide (Quinamed(R)) was the first naphthalimide analog that reached the clinical trial stage and exhibited excellent antitumour activity against advanced breast cancer. In this review, we make attempts to report recent advances on the synthesis of naphthalimide analogs, including mononaphthalimides, bisnaphthalimides, and naphthalimide-other heterocycles conjugates; in the meantime, the relationships between the structures of the naphthalimides and the antitumour activity are investigated in detail. It will pave the way for the design and development of naphthalimide analogs as anticancer agents.
Similar articles
-
Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.Chem Biol Drug Des. 2011 Dec;78(6):941-7. doi: 10.1111/j.1747-0285.2011.01232.x. Epub 2011 Sep 29. Chem Biol Drug Des. 2011. PMID: 21958160
-
Naphthalimides and azonafides as promising anti-cancer agents.Curr Med Chem. 2009;16(10):1192-213. doi: 10.2174/092986709787846659. Curr Med Chem. 2009. PMID: 19355879 Review.
-
5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.Bioorg Med Chem. 2011 Jan 15;19(2):961-7. doi: 10.1016/j.bmc.2010.11.055. Epub 2010 Nov 30. Bioorg Med Chem. 2011. PMID: 21208805
-
Synthesis, in vitro evaluation and molecular modelling of naphthalimide analogue as anticancer agents.Eur J Med Chem. 2013 Oct;68:352-60. doi: 10.1016/j.ejmech.2013.07.027. Epub 2013 Aug 11. Eur J Med Chem. 2013. PMID: 23994328
-
1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.Chem Rec. 2017 Oct;17(10):956-993. doi: 10.1002/tcr.201600134. Epub 2017 Apr 4. Chem Rec. 2017. PMID: 28375569 Review.
Cited by
-
NI-BODIPY-GO Nanocomposites for Targeted PDT.ACS Omega. 2023 Feb 22;8(9):8320-8331. doi: 10.1021/acsomega.2c06900. eCollection 2023 Mar 7. ACS Omega. 2023. PMID: 36910926 Free PMC article.
-
Design, Synthesis and Evaluation of Naphthalimide Derivatives as Potential Anticancer Agents for Hepatocellular Carcinoma.Molecules. 2017 Feb 22;22(2):342. doi: 10.3390/molecules22020342. Molecules. 2017. PMID: 28241441 Free PMC article.
-
Gamma radiation coupled ADP-ribosyl transferase activity of Pseudomonas aeruginosa PE24 moiety.Appl Microbiol Biotechnol. 2023 Mar;107(5-6):1765-1784. doi: 10.1007/s00253-023-12401-x. Epub 2023 Feb 18. Appl Microbiol Biotechnol. 2023. PMID: 36808279 Free PMC article.
-
UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells.Exp Ther Med. 2018 Nov;16(5):3921-3928. doi: 10.3892/etm.2018.6675. Epub 2018 Sep 3. Exp Ther Med. 2018. PMID: 30344670 Free PMC article.
-
Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.Bioorg Med Chem. 2015 Jul 1;23(13):3135-46. doi: 10.1016/j.bmc.2015.04.079. Epub 2015 May 6. Bioorg Med Chem. 2015. PMID: 26001344 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources